Jhos2

Manufactured by RIKEN BioResource Center

Sourced in Japan

The JHOS2 is a high-throughput, automated cell culture system developed by RIKEN BioResource Center. It is designed to efficiently maintain and monitor cell cultures in a controlled environment. The JHOS2 automates various cell culture tasks, such as media exchange, passaging, and monitoring, to streamline laboratory workflows.

Automatically generated - may contain errors

Lab products found in correlation

Skov3, by American Type Culture Collection (2 mentions) Jhos 4, by RIKEN BioResource Center (2 mentions) Ovcar3, by Thermo Fisher Scientific (1 mentions) Ovcar3, by American Type Culture Collection (1 mentions) Streptomycin, by Thermo Fisher Scientific (1 mentions) Penicillin, by Thermo Fisher Scientific (1 mentions) Ovk18, by Thermo Fisher Scientific (1 mentions) Ovk18, by American Type Culture Collection (1 mentions) Fetal bovine serum (fbs), by Thermo Fisher Scientific (1 mentions) Wi 38, by American Type Culture Collection (1 mentions) Dmem medium, by Fujifilm (1 mentions) Rpmi 1640 medium, by Fujifilm (1 mentions) Penicillin streptomycin, by Fujifilm (1 mentions) 5 aza 2 deoxycytidine dac, by Merck Group (1 mentions) Dmem ham s f 12 medium, by Fujifilm (1 mentions) Nih ovcar3, by RIKEN BioResource Center (1 mentions) Skov3, by Fujifilm (1 mentions) Rpmi 1640, by Thermo Fisher Scientific (1 mentions) 293ft cell, by Thermo Fisher Scientific (1 mentions) Ov2944 hm 1 hm 1 mouse ovarian cancer cell line, by RIKEN BioResource Center (1 mentions)

5 protocols using jhos2

Ovarian Cancer Cell Line Characterization

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human EOC cell line JHOC-5 was kindly provided by Dr Kazunori Ochiai (Jikei University, Tokyo, Japan). Cell lines RMG-I, RMG-II, RMG-V, RMUG-L, and RMUG-S were established and maintained at our laboratory. JHOS-2 was purchased from RIKEN Bioresource Center Cell Bank (Tsukuba, Japan). OVCAR3 and OVK18 were purchased from the American Type Culture Collection (Rockville, MD, USA). Cell lines JHOC-5, RMG-I, RMG-II, and RMG-V were clear-cell subtypes, JHOS-2 and OVCAR3 were serous subtypes, RMUG-S and RMUG-L were mucinous subtypes and OVK18 was endometrioid subtype. Cells were grown in Dulbecco's modified Eagle's medium (DMEM)/F12 (JHOC-5, RMG-II, JHOS-2, RMUG-L, and RMUG-S), RPMI-1640 (OVCAR3 and OVK18), or F12 (RMG-I) supplemented with 10% heat-inactivated FBS, 100 μg ml⁻¹ streptomycin (Life Technologies Inc., Grand Island, NY, USA), and 100 IU ml⁻¹ penicillin (Life Technologies Inc.). The cell lines used in our study were authenticated by short tandem repeat profiling on January 2012.

Nishio H., Yaguchi T., Sugiyama J., Sumimoto H., Umezawa K., Iwata T., Susumu N., Fujii T., Kawamura N., Kobayashi A., Park J., Aoki D, & Kawakami Y. (2014). Immunosuppression through constitutively activated NF-κB signalling in human ovarian cancer and its reversal by an NF-κB inhibitor. British Journal of Cancer, 110(12), 2965-2974.

+ Open protocol

+ Expand

Ovarian Cancer Cell Line Cultivation and 5-Aza-2'-Deoxycytidine Treatment

Check if the same lab product or an alternative is used in the 5 most similar protocols

The serous ovarian cancer cell lines JHOS‐2, JHOS‐4 and NIH‐OVCAR3 were obtained from RIKEN BioResource Center (Tsukuba, Japan). WI‐38 and SKOV3 (epithelial ovarian cancer) were obtained from ATCC (Manassas, VA, USA). Although these cell lines were not authenticated, relatively low passage number cells were obtained. JHOS‐2 and JHOS‐4 were maintained in DMEM/Ham's F‐12 medium (Wako, Osaka, Japan), NIH‐OVCAR3 and SKOV3 were maintained in RPMI‐1640 medium (Wako), and WI‐38 was maintained in DMEM medium (Wako). All cell lines were cultured in medium containing 5% FBS (Thermo Fisher Scientific, Waltham, MA, USA) and 1% penicillin‐streptomycin (Wako) at 37°C in a humidified incubator with 5% CO₂. For 5‐aza‐2′‐deoxycytidine (DAC, Sigma‐Aldrich, St Louis, MO, USA) treatment, cells were treated with 500 nmol/L DAC for 3 days. Medium containing DAC was replaced every day. DNA and RNA were extracted on the 7th day following the treatment.

Mase S., Shinjo K., Totani H., Katsushima K., Arakawa A., Takahashi S., Lai H., Lin R., Chan M.W., Sugiura‐Ogasawara M, & Kondo Y. (2019). ZNF671 DNA methylation as a molecular predictor for the early recurrence of serous ovarian cancer. Cancer Science, 110(3), 1105-1116.

+ Open protocol

+ Expand

Culturing Human Ovarian Cancer Cell Lines

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

The OV2944-HM-1 (HM-1) mouse ovarian cancer cell line and JHOS2 were purchased from RIKEN BioResource Center and were cultured as previously described in ref. ^{14 (link),31 (link)}. Human ovarian cancer cell lines (OVCAR8, OVCA433, and A1847) were provided by Dr. Susan K. Murphy from Duke University. These cells were cultured and maintained in RPMI1640 (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 g/mL streptomycin in an atmosphere containing 5% CO₂ at 37 °C. 293FT cells were purchased from Thermo Fisher Scientific (Waltham, MA, USA) and cultured as described in ref. ^{32 (link)}. Throughout this study, we used cell lines that were passaged fewer than 30 times. All cell lines were regularly tested for mycoplasma contamination.

Taki M., Abiko K., Baba T., Hamanishi J., Yamaguchi K., Murakami R., Yamanoi K., Horikawa N., Hosoe Y., Nakamura E., Sugiyama A., Mandai M., Konishi I, & Matsumura N. (2018). Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation. Nature Communications, 9, 1685.

+ Open protocol

+ Expand

Sourcing and Culturing Ovarian Cancer Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

The human OVC lines SKOV3, CAOV3, JHOC5, A2780, ES2, and TOV112D were kindly provided by Carla Grandori (Fred Hutchinson Cancer Research Center, Seattle, WA, USA). OV-MIU, OV-MANA, and KURAMOCHI lines were obtained from the JCRB (Ibaraki, Japan). JHOS2 and JHOS4 lines were obtained from the RIKEN BioResource Center (Ibaraki, Japan). All cell lines were cultured in DMEM supplemented with 10% FBS under standard culture conditions.

Kudo K., Nomura M., Sakamoto Y., Ito S., Morita M., Kawai M., Yamashita Y., Ito K., Yamada H., Shima H., Yaegashi N, & Tanuma N. (2020). Divergent metabolic responses dictate vulnerability to NAMPT inhibition in ovarian cancer. FEBS letters, 594(9).

+ Open protocol

+ Expand

Cell Culture Conditions for Cancer Research

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

RPE1-hTERT p53^−/− Cas9
(Zimmermann et al., 2018 (link)) and
293T cells were grown in DMEM supplemented with 10% FBS (Wisent
#080150), GlutaMAX (life Technologies #35050–061) and 1%
Pen/Strep (Wisent #450–201-EL). UWB1.28, SKOV3 and OV90 cells
were purchased from ATCC. UWB1.28 cells were grown in RPMI: MEGM (1:1)
supplemented with 3% FBS and 1% Pen/Strep. SKOV3 cells were grown in
McCoys 5a supplemented with 10% FBS and 1% Pen/Strep. OV90 cells were
grown in MCDB 105: Medium 99 (1:1) supplemented with 1% sodium
bicarbonate (0.75 g/L), 15% FBS and 1% Pen/Step. JHOS2 were purchased
from Riken BRC and grown in DMEM: F-12(1:1) supplemented with 10%FBS,
0.1mM NEAA. SUM149PT cells were purchased from Asterand BioScience and
grown in a DMEM/F12 medium mixture supplemented with 5% FBS, 1%
Pen/Strep, 1 μg/mL hydrocortisone and 5 μg/mL insulin.
COV362 and COV644 were purchased from Sigma and grown in DMEM
supplemented with 10% FBS and 1% Pen/Strep. RMUGS cells were purchased
from JCRC cell bank and grown in Ham’s 12 supplemented with 10%
FBS and 1% Pen/Strep. Wild-type and
BRCA2^−/−DLD-1 cells were purchased from Horizon and maintained in RPMI medium
supplemented with 10% FBS, 1% Pen/Strep and 2 mM sodium pyruvate. All
cell lines were grown at 37 °C and 5% CO2.

Álvarez-Quilón A., Wojtaszek J.L., Mathieu M.C., Patel T., Appel C.D., Hustedt N., Rossi S.E., Wallace B.D., Setiaputra D., Adam S., Ohashi Y., Melo H., Cho T., Gervais C., Muñoz I.M., Grazzini E., Young J.T., Rouse J., Zinda M., Williams R.S, & Durocher D. (2020). Endogenous DNA 3′ blocks are vulnerabilities for BRCA1 and BRCA2 deficiency and are reversed by the APE2 nuclease. Molecular cell, 78(6), 1152-1165.e8.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!